Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
详细信息 查看全文
- 作者：Sameer S. Udhanea ; b ; Bernhard Dickb ; c ; Qingzhong Hud ; 1 ; Rolf W. Hartmannd ; e ; Amit V. Pandeya ; b ; amit@pandeylab.org" class="auth_mail" title="E-mail the corresponding author
- 关键词：CYP17A1 ; Orteronel ; Abiraterone ; CYP21A2 ; PCOS ; Premature adrenarche ; Castration resistant prostate cancer
- 刊名：Biochemical and Biophysical Research Communications
- 出版年：2016
- 出版时间：2 September 2016
- 年：2016
- 卷：477
- 期：4
- 页码：1005-1010
- 全文大小：773 K
文摘
- •
CYP17A1 is a target of anti-prostate cancer drugs.
- •
Abiraterone, orteronel and galeterone target CYP17A1.
- •
Effect on adrenal steroid metabolome by CYP17A1 inhibitors was studied.
- •
Orteronel was specific for CYP17A1 but abiraterone inhibited CYP21A2 activity.
- •
Orteronel may be used to treat hyperandrogenic disorders without side effects.